Commercial Alamar, Hemab, Kailera, and Seaport advance IPOs PharmaphorumThe last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings.CommercialRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum The last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings. CommercialRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Spyre drug for inflammatory bowel disease shows promise in early studyNext: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Related Stories Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026 Commercial Lilly launches its LillyDirect sales channel in the UK pharminent June 25, 2026
